FI112866B - Menetelmä uusien, terapeuttisesti käyttökelpoisten, heksahydro-8-hydroksi-2,6-metano-2H-kinolitsiinien amidijohdannaisten valmistamiseksi sekä menetelmässä käytettävät välituotteet - Google Patents

Menetelmä uusien, terapeuttisesti käyttökelpoisten, heksahydro-8-hydroksi-2,6-metano-2H-kinolitsiinien amidijohdannaisten valmistamiseksi sekä menetelmässä käytettävät välituotteet Download PDF

Info

Publication number
FI112866B
FI112866B FI922695A FI922695A FI112866B FI 112866 B FI112866 B FI 112866B FI 922695 A FI922695 A FI 922695A FI 922695 A FI922695 A FI 922695A FI 112866 B FI112866 B FI 112866B
Authority
FI
Finland
Prior art keywords
methano
formula
trans
octahydro
quinolizin
Prior art date
Application number
FI922695A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI922695A0 (fi
FI922695A (fi
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI922695A0 publication Critical patent/FI922695A0/fi
Publication of FI922695A publication Critical patent/FI922695A/fi
Application granted granted Critical
Publication of FI112866B publication Critical patent/FI112866B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
FI922695A 1991-06-11 1992-06-10 Menetelmä uusien, terapeuttisesti käyttökelpoisten, heksahydro-8-hydroksi-2,6-metano-2H-kinolitsiinien amidijohdannaisten valmistamiseksi sekä menetelmässä käytettävät välituotteet FI112866B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91401550A EP0517984A1 (de) 1991-06-11 1991-06-11 Amidanaloge-Derivate von methanoverbrückten Chinolizinen
EP91401550 1991-06-11

Publications (3)

Publication Number Publication Date
FI922695A0 FI922695A0 (fi) 1992-06-10
FI922695A FI922695A (fi) 1992-12-12
FI112866B true FI112866B (fi) 2004-01-30

Family

ID=8208580

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922695A FI112866B (fi) 1991-06-11 1992-06-10 Menetelmä uusien, terapeuttisesti käyttökelpoisten, heksahydro-8-hydroksi-2,6-metano-2H-kinolitsiinien amidijohdannaisten valmistamiseksi sekä menetelmässä käytettävät välituotteet

Country Status (16)

Country Link
EP (2) EP0517984A1 (de)
JP (1) JP3377227B2 (de)
KR (1) KR100234926B1 (de)
AT (1) ATE214392T1 (de)
AU (1) AU649836B2 (de)
CA (1) CA2070573C (de)
DE (1) DE69232473T2 (de)
DK (1) DK0518767T3 (de)
ES (1) ES2173863T3 (de)
FI (1) FI112866B (de)
HU (1) HU212735B (de)
IE (1) IE921874A1 (de)
IL (1) IL102132A (de)
NO (1) NO305124B1 (de)
NZ (1) NZ243031A (de)
PT (1) PT518767E (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
NZ249346A (en) * 1992-02-24 1995-10-26 Merrell Dow Pharma 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
WO1999025356A1 (en) * 1997-11-14 1999-05-27 Akzo Nobel N.V. Use of mirtazapine for treating sleep apneas
US7160898B2 (en) 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
PT1066036E (pt) 1998-02-27 2006-09-29 Univ Illinois Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US20070203176A1 (en) * 2006-01-05 2007-08-30 Janos Hajko Crystalline forms of dolasetron base and processes for preparation thereof
CN101774971B (zh) * 2010-02-10 2011-07-27 山东众诚药业股份有限公司 高纯度1-甲基吲唑-3-羧酸的生产方法
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB219363A (en) * 1923-03-24 1924-07-24 Abraham Preston Improvements in or in connection with bed couches
EP0200444B1 (de) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-HT-antagonistischer Wirkung
EP0330788A1 (de) * 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln zur Behandlung von Herz-Arrhythmie
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
ATE214392T1 (de) 2002-03-15
JP3377227B2 (ja) 2003-02-17
HU9201939D0 (en) 1992-08-28
NO305124B1 (no) 1999-04-06
NO922270L (no) 1992-12-14
CA2070573A1 (en) 1992-12-12
NZ243031A (en) 1994-02-25
CA2070573C (en) 2003-04-15
IL102132A0 (en) 1993-01-14
AU1803792A (en) 1992-12-24
DE69232473D1 (de) 2002-04-18
IE921874A1 (en) 1992-12-16
NO922270D0 (no) 1992-06-10
EP0518767A3 (en) 1993-05-05
HUT61549A (en) 1993-01-28
KR930000518A (ko) 1993-01-15
HU212735B (en) 1996-10-28
JPH05202044A (ja) 1993-08-10
EP0518767B1 (de) 2002-03-13
AU649836B2 (en) 1994-06-02
DK0518767T3 (da) 2002-07-01
KR100234926B1 (ko) 1999-12-15
PT518767E (pt) 2002-09-30
ES2173863T3 (es) 2002-11-01
FI922695A0 (fi) 1992-06-10
EP0517984A1 (de) 1992-12-16
EP0518767A2 (de) 1992-12-16
DE69232473T2 (de) 2002-11-21
IL102132A (en) 1996-10-31
FI922695A (fi) 1992-12-12

Similar Documents

Publication Publication Date Title
KR100263414B1 (ko) 티에노 [3,2-b] 피리딘 유도체
US5011846A (en) Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5292736A (en) Morpholinoalkylindenes as antiglaucoma agents
FI112866B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten, heksahydro-8-hydroksi-2,6-metano-2H-kinolitsiinien amidijohdannaisten valmistamiseksi sekä menetelmässä käytettävät välituotteet
JP2000512645A (ja) スルホンアミド誘導体およびｃｎｓ障害の治療におけるそれらの使用
DE69111816T4 (de) Indolederivate und ihre verwendung als serotonin-antagoniste.
JPH02256670A (ja) インダゾール―３―カルボキサミド誘導体及びそれを有効成分とするセロトニン３受容体拮抗剤
JP2002030084A (ja) １−アザビシクロアルカン化合物およびその医薬用途
BG63083B1 (bg) Заместени тетрациклични тетрахидрофуранови производни
SK50192004A3 (sk) Spôsob prípravy (S)-4-amino-5-chlór-2-metoxy-N-[1-[1-(2- tetrahydrofurylkarbonyl)-4-piperidinylmethyl]-4- piperidinyl]benzamidu, farmaceutický prostriedok obsahujúci tento derivát a opis medziproduktu tohto derivátu
US5955470A (en) Derivatives of amide analogs of certain methano bridged quinolizines
JP2001512727A (ja) ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
IE83573B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
WO1995009167A1 (fr) Derive d'indoline et antagoniste du recepteur 5-ht3 contenant ce derive et utilise comme ingredient actif
SK9398A3 (en) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2- -methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
US5525600A (en) (Thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
DK175643B1 (da) Anvendelse af quinolizin- og quinolizinon-derivater ved fremstilling af lægemidler
US5081128A (en) 2,3-dihydro-1h-isoindole derivatives and their application in therapy
JPH09512025A (ja) ５ｈｔ▲下２ｃ▼および５ｈｔ▲下２ｂ▼アンタゴニストとしての三環式誘導体
US4968792A (en) Psychotropic benzisothiazole derivatives
JPS6038377A (ja) 新規ベンゾフラン誘導体、その製造法および該誘導体を含む医薬組成物
IE64043B1 (en) Aroyl-ureas
JP2003081978A (ja) スピロ環式化合物およびその医薬用途
NZ249346A (en) 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof
JPH0386876A (ja) ベンゾイソキノリン誘導体

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS INC.

Free format text: AVENTIS INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired